Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 3 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A

3(60.0%)

Phase 2

1(20.0%)

Phase 1

1(20.0%)

5Total

N/A(3)

Phase 2(1)

Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT05305079Completed

NA-AION Risk Factors: New Perspectives

Role: collaborator

NCT04041856Phase 1Unknown

Povidone-iodine 2% Eye Drop Versus Artificial Tear Drop for Treatment of Adenoviral Keratoconjunctivitis

Role: lead

NCT03138785Not ApplicableUnknown

UVX as an Adjuvant in the Treatment of Fungal Keratitis

Role: lead

NCT02900365Not ApplicableCompleted

Early Vs Late Post Traumatic Cataract Surgery

Role: lead

NCT02663141Phase 2Completed

Randomized Clinical Trial of Intravitreal Bevacizumab Versus Intravitreal Bevacizumab Combined With Losartan in the Treatment of Diabetic Macular Edema

Role: collaborator

NCT02716883Not ApplicableUnknown

Early Amniotic Membrane Transplantation in Bacterial Keratitis

Role: lead

All 6 trials loaded